Research Studies

Bitch to Quit

The Bitch to Quit smoking cessation research study is closed to additional enrollment. If you participated in the study and are looking for follow-up information, please contact Raymond Ruiz at rar2175@uic.edu or 312.996.7974 with any questions or concerns. Information about study findings will be posted in the near future.

Medication Therapy Management Study

Gilead GS-US-366-1216

A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) If you are interested in participating, please contact Kenyetta Drummond in the Research Department at 773.572.5116 or email KenyettaD@howardbrown.org.

Gilead GS-US-311-1717

A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed on Regimens containing ABC/3TC . If you are interested in participating, please contact Kenyetta Drummond in the Research Department at 773.572.5116 or email KenyettaD@howardbrown.org.

Bristol-Myers Squibb, AI438047

A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV. If you are interested in participating, please contact Kenyetta Drummond in the Research Department at 773.572.5116 or email KenyettaD@howardbrown.org.

Gilead GS-US-380-1844

A Phase 3, Randomized, Double-Blind Study to Evaluate Switching from a Regimen containing Dolutegravir and ABC/3TC to a Fixed Dose Combination of GS-9883/F/TAF in HIV 1 Infected Subjects who are Virologically Suppressed. If you are interested in participating, please contact Kenyetta Drummond in the Research Department at 773.572.5116 or email KenyettaD@howardbrown.org.

Gilead GS-US-380-1878

A Phase 3 Randomized, Open Label Study to Evaluate Switching from Regimens Consisting of Ritonavir-boosted Darunavir or Atazanavir plus either Emtricitabine/Tenofovir Fixed-Dose Combination (FTC/TDF) or Abacavir/3TC (ABC/3TC) FDC to a Fixed Dose Combination (FDC) of GS-9883/F/TAF in HIV-1 Infected Subjects who are Virologically Suppressed. If you are interested in participating, please contact Kenyetta Drummond in the Research Department at 773.572.5116 or email KenyettaD@howardbrown.org.

Gilead GS-US-380-1489

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults. If you are interested in participating, please contact Kenyetta Drummond in the Research Department at 773.572.5116 or email KenyettaD@howardbrown.org.

Gilead GS-US-380-1490

A Phase 3, Randomized, Double-Blinded Study of the Safety and Efficacy of a Fixed Dose Combination of GS-9883/ Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV 1 Infected, Antiretroviral Treatment-Naïve Adults. If you are interested in participating, please contact Kenyetta Drummond in the Research Department at 773.572.5116 or email KenyettaD@howardbrown.org.

Upcoming Events

  1. Garden of Eve: Forward

    April 28 @ 6:00 pm - 10:00 pm